

Martin Grossmann

## Entrepreneurship in Biotechnology

Managing for Growth from Start-Up to Initial Public Offering

With 95 Figures and 24 Tables

Physica-Verlag

A Springer-Verlag Company

## **Table of Contents**

For	eword	(by T.J. Allen)	VII
For	eword	(by J. Meier)	IX
Pre	face		XI
1	Ind Spec	ependent Biopharmaceutical Companies and Their cialization in Drug Discovery Technologies	1
	1.1	Drug Discovery in Research and Development Pipelines	1
	1.2	Growth Problems Generated by R&D Duration	14
	1.3	Consequences of Human Genetic Research on Drug Discovery	20
2	Moo Beh	lel Structure for High-Technology Firms and Its Dynamic avior in Start-Up Phases	33
	2.1	Macro Structure for Entrepreneurial Management of Start-Ups	
		2.1.1 System Dynamics as Research Methodology	33
		2.1.2 Advancement of a Novel Disease Target Technology as Phase Objective	42
		2.1.3 Impacts of Entrepreneurial Confidence on Voluntary Leaving, Absorptive Capacity, and Corporate Planning Horizon.	49
	2.2	Micro Structure that Determines High-Technology Performance	
		2.2.1 Average Research Experience of Scientists	59
		2.2.2 Diversity of Scientific Disciplines	
		2.2.3 Research Quality as Dependent on Understanding of	
		Failures	
	2.3	Dynamic Behavior from Start-Up Model Experiments	79
		2.3.1 Surprise Behavior of Technology Effectiveness	79
		2.3.2 Start-Up Success as Determined by Conditions of Corporate Foundation	
		2.3.3 Policy Design to Accelerate Start-Up Success	. 111

3	Model Structure and Dynamic Behavior for High-Technology			
	Firn	ns in Transition to Growth Phases1	27	
	3.1	Macro Structure for Contract Research1	27	
		3.1.1 Scope of Transition Model, Boundaries, and Time Horizon 1 3.1.2 Feedback Structures for Growth and Growth Saturation1	27 30	
		3.1.3 Principal-Agent Theory to Investigate Research Contracts1	35	
	3.2	Micro Structure for Contract Research on Novel Disease Targets 1	42	
		3.2.1 Industry Demand for Research Contracts1	42	
		3.2.2 Planning of Scientific Laboratory Personnel	48	
		3.2.3 Obsolescence/Irrelevance of Scientific Experience and Contract Research Funding	50	
	3.3	Dynamic Behavior from Transition Model Experiments1	54	
		3.3.1 Simulation Studies on Corporate Transition1	54	
		3.3.2 Attractiveness Fluctuations from Technology Effectiveness	62	
		3.3.3 Firm Value from Contract Research Funds	67	
4	Eco Cap	nomic Value Creation in Transition Phases: Access to Equity oital1	73	
	4.1	Value Creation from Drug Candidates in Collaborative R&D Pipelines1	73	
		4.1.1 Flow of Drug Candidates Through Pipeline Phases	173	
		4.1.2 Present Value of Royalty Expectations from Drug Candidates	188	
		4.1.3 Capital Asset Pricing Model for Discount Rate Estimation1	193	
	4.2	Simulation of Value Creation	197	
		4.2.1 Present Values of Pipeline Phases	197	
		4.2.2 Option Premium as a Complement to Present Value	202	
		4.2.3 Option Premium and Present Value for Investment		
		Decisions	209	
	4.3	Equity Financing for Growth Phases	223	
		4.3.1 Fund-Raising Success as Determine by Value Creation in R&D.	223	

4.3.2 Attractiveness to Investors from Research Track Record and Collaborative Partnership	227					
4.3.3 Sensitivity of Fund-Raising Success to Value Creation in						
R&D	233					
5 Strategies for Growth Phases to Sustain Independence	237					
Bibliography Appendix 1: Parameter List for Start-Up Model Appendix 2: List of Equations for Start-Up Model						
					Appendix 3: Parameter List for Transition Model	299
					Appendix 4: A Dynamic Theory on Cost of Capital for	
Biotechnology Firms	301					
1. Dependency of Cost of Capital on R&D Pipeline Phases	. 301					
<ol> <li>Leverage Concept to Explain Cost of Capital for Investment in R&amp;D Projects.</li> </ol>						
3. Consequences for Management Decisions						
Index						